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ABSTRACT: We report on the synthesis and operation of a three-barrier, rotaxane-based, artificial molecular machine 
capable of sequence-specific beta-homo (3) peptide synthesis. The machine utilizes non-proteinogenic 3-amino acids, a 
class of amino acids not generally accepted by the ribosome, particularly consecutively. Successful operation of the ma-
chine via native chemical ligation (NCL) demonstrates that even challenging 15- and 19-membered ligation transition 
states are suitable for information translation using this artificial molecular machine. The peptide-bond-forming catalyst 
region can be removed from the transcribed peptide by peptidases; artificial and biomachines working in concert to gen-
erate a product that cannot be made by either machine alone. 
INTRODUCTION 
Biomolecular machinery often carries out molecular 
construction with high efficiency and exquisite selectivi-
ty.1 A stand-out example is the ribosome,2 which trans-
lates genetic information encoded in an mRNA strand via 
the sequence-specific assembly of tRNA-loaded amino 
acid building blocks, generally beginning with the start-
codon AUG which encodes for methionine.3 However, the 
ribosome is incapable of the consecutive addition of un-
natural D-amino acids,4,5 even when they are functional-
ized with natural tRNA codons. Although bioengineering 
can go some way to addressing these limitations, modest 
changes to substrate or machine often lead to a loss of 
function in a largely unpredictable manner.6  
Chemical routes to sequence-defined polymers are be-
ing developed,7 including the use of artificial small-
molecule machines8 and DNA-based9 templates and ma-
chines. Determining the structural tolerance and versatili-
ty of such systems is important. A rotaxane-based ma-
chine10 that sequentially adds successive -amino acids to 
a growing peptide chain has previously been described.8 
The design uses native chemical ligation11 (NCL) to trans-
late sequence information from the molecular machine 
thread into the newly synthesized oligomer. The synthesis 
of non-proteinogenic 3-peptides is an intriguing target 
for artificial molecular machines, as 3-peptides are not 
normally made by natural ribosomes12 and they exhibit 
enhanced biostability relative to their -peptide conge-
ners.13 Here we report on the modular synthesis and se-
quence-specific operation of a rotaxane-based molecular 
machine bearing three 3-amino acid building blocks. 
Operating through challengingly sized NCL transition 
states, the molecular device assembles a mixed 3-
hexapeptide of defined sequence. Furthermore, the inher-
ent selectivity of peptidases allows the peptide sequence 
to be selectively hydrolyzed at the C-terminus -amino 
acid region to liberate the 3-peptide fragment from the 
artificial translation machinery through which it was as-
sembled. 
RESULTS AND DISCUSSION 
In order to construct the full molecular machine from a 
single barrier [2]rotaxane synthon,8e and to confirm that 
the extra carbon atom in 3-amino acids does not prevent 
them acting as barriers to macrocycle shuttling along the 
rotaxane thread, we prepared rotaxane 1 (Scheme 1). Cop-
per-catalyzed active metal template14 synthesis of 
[2]rotaxane 1, bearing a 3-Phe amino acid barrier, was 
carried out using minor modifications to a previously re-
ported protocol for an -phenylalanine blocking group 
(Scheme 1).8e Treatment of macrocycle 2 with 
CuPF6·(MeCN)4, followed by addition of bulky azide 3 and 

3-amino acid-bearing group 4 afforded rotaxane 1 in 40 % 
yield, accompanied by 7 % of free thread 5. 
The mechanically interlocked structure of 1 was con-
firmed by 1H NMR spectroscopy and mass spectrometry 
(Figure 1 and Supporting Information). In comparison 
with non-interlocked components 2 and 5, rotaxane 1 fea-
tures significant upfield shifts of proton resonances on 
both the triazole (He) and the n-propyl tether (Hd and Hc), 
consistent with shielding from the aromatic rings of the 
macrocycle. Similar shielding effects occur for several 
macrocycle protons (e.g. HD, HE and HF), in addition to 
diastereotopic splitting of HE and HD caused by the un-
symmetrical threaded axle. Protons Hh, Hi and Hj experi-
ence negligible shifts, indicating that the macrocycle re-
sides over a distal region of the thread. Rotaxane 1 did not 
dethread in solution over several weeks. 
 
Scheme 1. Active Metal Template Synthesis of Rotax-
ane Synthon 1a 
 
 
aReagents and conditions: (i) 2 (1.5 equiv.), 
CuPF6·(MeCN)4 (0.5 equiv.), 3 (6 equiv.), 4 (1 equiv.), 
CH2Cl2:




Figure 1. 1H NMR spectra (600 MHz, d6-acetone, 298 K) 
of (i) macrocycle 2, (ii) rotaxane 1, (iii) free thread 5. The 
assignments correspond to the lettering shown in 
Scheme 1.  
Having established the structure and stability of the 
one-barrier rotaxane synthon, our attention turned to the 
assembly of three-barrier molecular machine 6 (Scheme 
2). Rotaxane 1 and two-barrier extension unit 7 were 
joined by a CuAAC reaction in close-to-quantitative yield 
(Scheme 2, step (i)), followed by hydrazone formation via 
the direct condensation of Boc-Gly-Gly-Cys(Trt)-NHNH2 
-peptide catalytic unit hydrazide 8 (Scheme 2, step (ii)). 
This formed 6, a rotaxane-based molecular machine bear-
ing three different non-proteinogenic amino acid building 
blocks appropriate for the sequence-specific assembly of a 

3-peptide.  
Following cleavage of the acid-labile Boc and trityl 
groups of 6 with trifluoroacetic acid (TFA) and triiso-
propylsilane (TIPSH), molecular machine 9 was operated 
for 7 days in the presence of triethylamine (Scheme 2). In 
successive NCL iterations, the macrocycle removes each 
amino acid barrier in turn, each cleavage event allowing 
the ring to move further along the length of the rotaxane 
axle in order to access the next barrier.8 Reaction with 
barriers out of sequence is prevented by the compartmen-
talization of the macrocycle and the rigidity of the thread, 
which holds non-proximal barriers out of reach of the 
cysteine ‘arm’. Following the transfer of all the amino acid 
groups from the track to the elongation site tethered to 
the macrocycle, the ring dethreads from the end of the 
track into the bulk medium.  
We found that the 3-Phe and 3-Leu residues attached 
to the track via phenolic ester linkages were more prone 
to hydrolysis during the Boc and trityl deprotection stage 
of 6 than the -amino acids used in previous rotaxane 
machine systems,8 which led us to optimize the condi-
tions for step (iii), Scheme 2, by adding TIPSH. Pivaloyl 
protection of 3-Ala renders the phenolic ester stable to 
the deprotection conditions. Notably, when partial loss of 

3-Phe and/or 3-Leu occurred during the deprotection 
step, subsequent operation of the machine translated the 
sequence of amino acids that remained, including se-
quences missing hydrolyzed residues, with high fidelity 
into the corresponding sequence-specific operation prod-
ucts (see Supplementary Information for details). This 
provides further confirmation that incorrect sequences 
produced by these types of molecular machines are readi-
ly detected during the analysis of the operation products.  
After operation of molecular machine 9 under the op-
timized conditions shown in Scheme 2, mass spectral 
analysis showed complete consumption of 9 and the for-
mation of 10 and amino-acid-free track 11. Following sol-
vent removal and purification of the crude mixture by 
preparative TLC, 10 was converted to S,N-acetal 12 in line 
with previous systems.8  
  
Scheme 2: Synthesis and Operation of a Three-Barrier Machine Bearing Non-Proteinogenic 3-Amino Acidsa  
 
aReagents and conditions: (i) CuPF6·(MeCN)4 (1.5 equiv.), Tentagel
TM TBTA resin, CH2Cl2:
tBuOH (4:1), r.t., 48 h, 97 %. 
(ii) Boc-Gly-Gly-Cys(Trt)-NHNH2 (8), aniline, CH2Cl2, r.t. 48 h, 72 %. (iii) TFA, TIPSH, CH2Cl2, r.t., 1 h. (iv) Et3N 
(44 equiv.), PPh3 (3.5 equiv.), DMF, 60 °C, 7 d, 29 % over 2 steps (58 % based on macrocycle).  
The sequence fidelity of the peptidic product, 12, from 
the operation of machine 9 was confirmed by tandem 
mass spectrometry (MS-MS, Figure 2). The most intense 
MS-MS fragmentation profile was achieved with the 
[12+2H]2+ mass-ion. Fragmentation showed iterative 
cleavage of the amide bonds of the assembled 3-peptide 
backbone down to the parent macrocycle, consistent with 
the expected sequence. Seebach has shown that peptide 
oligomers containing 3-amino acids undergo additional 
fragmentation to their -amino acid congeners.15 Analysis 
of the MS-MS spectrum of [12+2H]2+ showed peaks con-
sistent with dehydration16 (Figure 2, shown in blue), retro-
Michael (Figure 2, shown in green, Y*) and retro-Mannich 
(Figure 2, shown in red, Yα) fragmentation pathways, fur-
ther confirmation of the successful sequence translation.  
The mass spectrometry results were corroborated by 
comparison with authentic material, prepared unambigu-
ously by conventional peptide synthesis. When operating 
pristine 9, obtained from 6 under conditions where hy-
drolysis does not occur, no fragment ions indicative of 








Figure 2. Tandem mass-spectrometry sequencing of 12. 
Analysis of doubly-charged [12+2H]2+ mass ions bearing 
the translated Piv-3Ala-3Leu-3Phe-Gly-Gly-Cys peptide 
sequence. (i) Fragmentation modes of - and 3-peptides. 
(ii) MS-MS spectrum of authentic standard of the antici-
pated product of operation. (iii) MS-MS spectrum of iso-
lated product of machine operation. Orange peaks indi-
cate amide bond N-C fragmentation; green peaks indicate 

3-peptide retro-Michael fragmentation; red peaks indi-
cate 3-peptide retro-Mannich fragmentation; blue peaks 
indicate addition or loss of water. 
 
A feature of the homologated (3) amino acids used in 9 
is that the size of the NCL [S-N] trans-acyl shift transition 
states differs from those used in the previously reported 
-peptide-forming rotaxane machines.8 Katritzky found 
that NCLs requiring 15- or 19-membered [S-N] acyl-
transfer transition states, the size employed in the opera-
tion of 9, are significantly slower than NCLs involving 11-, 
14- and 17-membered transition states (which featured in 
the operation of the -peptide-forming machines8).17 We 
attribute the longer reaction time necessary for complete 
operation of 9 (7 days cf. 3 days for -peptide-forming 
machines) to these less favorable transition state sizes. 
The successful in machina acyl-transfer of these challeng-
ing transition states, without sequence erosion, illustrates 
the robustness and structural tolerance of this type of 
molecular machine-promoted synthesis. 
Following the formation of peptide 10 from molecular 
machine 6, we investigated methods for cleaving the cys-
teine NCL catalyst unit, and adjacent GlyGly elongation 
site, from the translated amino acid sequence. We envis-
aged that the action of an endotopic protease could result 
in the selective digestion of the -region18d of the fused 

3-operation product 10, thereby liberating the translat-
ed 3-region. The basis for the anticipated selectivity 
stems from the high stability of -peptides to both in 
vitro18 and in vivo13b,19 enzymatic degradation. 
Initial studies indicated that removal of the cysteine 
thiol would ameliorate manipulation of 10, preventing 
both conversion to 12 and disulfide formation. Further-
more, removal of the macrocycle should increase compat-
ibility of the peptide with the aqueous conditions re-
quired for proteolysis. Machine product 10 was subjected 
to a sequence of reductive desulfurization mediated by 
radical initiator V-044,20 followed by macrocycle removal 
with methoxyamine·HCL to give alanine hydrazide deriv-
ative 13 (Scheme 3). Hydrazide 13 was submitted to prote-
olysis with subtilisin Carlsberg, a broad scope serine en-
dopeptidase that exhibits high stability and activity at 
elevated temperatures and optimal activity at pH 7–8.21 
After a five-day incubation period at 55 °C, ESI-(-)-MS 
analysis indicated the selective cleavage of the Ala–Gly 
amide bond to afford 14 in high yield. Longer incubation 
times and refreshment of the enzyme did not lead to the 
cleavage of other peptide residues. All of the 3-peptide 
links proved inert to enzymatic cleavage, as did the bridg-
ing - junction, consistent with previous observations 
on the action of peptidases on 3-peptides.13c,21b The Gly–
Gly link was also unaffected by subtilisin Carlsberg, pre-
sumably due to its proximity to the -peptide region.21b,22 
In contrast, incubation of 13 with Pronase, a mixture of 
broad scope endo- and exopeptidases isolated from Strep-
tomyces griseus,21b cleaved all of the amide bonds linking 
-amino acids to give 15, leaving only the bridging - 
junction and the - peptide bonds intact. The selective 
cleavage of amino acid residues from the residual catalytic 
arm of operation product 10 to give post-operationally 
modified 3-peptides 14 or 15 is reminiscent of the dele-
tion of N-terminal methionine residues (installed by the 
start-codon) from ribosomal proteins by methionine ami-


















 Scheme 3. Enzymatic Liberation of the 3-Peptide 
Region of the Machine Product from the NCL Cata-
lyst Site.a 
 
aReagents and conditions: (i) V-044 (0.2 equiv.), 
TCEP·HCl (10 equiv.), NEt3 (15 equiv.), 
tBuSH (10 equiv.), 
DMF:H2O (10:1), r.t., 65 h, 64 %. (ii) Methoxyamine·HCl, 
CHCl3/MeOH, reflux, 1 h, 75 %. (iii) Subtilisin Carlsberg 
(1 mg/mL), phosphate buffer (pH 8, 0.1 M), 50 °C, 5 days. 
(iv) Pronase (1 mg/mL), H2O, 37 °C, 4 days.  
CONCLUSIONS 
An artificial rotaxane-based small-molecule machine 
can successfully carry out the autonomous sequential 
synthesis of peptides containing 3-amino acids. Operat-
ing through 11- and particularly challenging 15- and 19-
membered NCL transition states, sequence information 
encoded into the molecular machine is transcribed into 
peptide products without detectable sequence scram-
bling. The structural tolerance of the small-molecule ma-
chine contrasts with that of natural ribosomes. Treatment 
of the small-molecule machine product with peptidases 
cleaves the NCL catalyst residue from the -peptide re-
gion, biological and artificial molecular machines working 
in concert to produce 3-peptide products inaccessible 
through either strategy alone.  
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